Dianthus Therapeutics, Inc. (DNTH)
| Market Cap | 2.39B |
| Revenue (ttm) | 3.08M |
| Net Income (ttm) | -126.35M |
| Shares Out | 43.22M |
| EPS (ttm) | -3.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 835,081 |
| Open | 53.15 |
| Previous Close | 53.11 |
| Day's Range | 52.47 - 56.77 |
| 52-Week Range | 13.37 - 57.50 |
| Beta | 1.23 |
| Analysts | Strong Buy |
| Price Target | 71.22 (+29.05%) |
| Earnings Date | Mar 11, 2026 |
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was... [Read more]
Financial Performance
In 2024, Dianthus Therapeutics's revenue was $6.24 million, an increase of 120.63% compared to the previous year's $2.83 million. Losses were -$84.97 million, 95.1% more than in 2023.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $71.22, which is an increase of 29.05% from the latest price.
News
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus Therapeutics, Inc. (DNTH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Dianthus Therapeutics, Inc. (DNTH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B ce...
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficac...
Dianthus Therapeutics to Participate in Four Investor Conferences During November
NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio...
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
NEW YORK and WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibod...
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibod...
Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call
Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call Company Participants Marino Garcia - President, CEO & Director Simrat Randhawa - Chief Medical Officer Confer...
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibod...
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthen...
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibod...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular fra...
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 an...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 ne...
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 ...
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibod...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropat...